MarketBeat
08 Aug 2026, 05:04 UTC · 6w ago
Verdict
Headline takes no side. We score EBS −0.20 across six claims — slightly bearish.
−0.20slightly bearish
More negative than 72% of ticker scores this week
What the story claims
6 claims · scored −1 bearish … +1 bullish
Emergent Biosolutions lowered its full-year 2026 revenue guidance from $720–$760 million to $645–$675 million.
More negative than 99% of claims this week
The company recorded a non-cash impairment charge of approximately $191 million related to the NARCAN asset group due to competitive and pricing pressures.
So whatLarge impairments indicate a permanent write-down in the value of a core asset, signaling diminished future cash flows from a primary product.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 95% of claims this week
Increased competition and aggressive pricing in the naloxone market are expected to weigh on NARCAN sales.
So whatMarket share erosion and price compression in a lead commercial product threaten long-term margins and revenue stability.
More negative than 91% of claims this week
Second-quarter revenue ($234 million) and adjusted EBITDA ($97 million) both exceeded prior guidance and analyst consensus.
More positive than 76% of claims this week
Which stocks this story touches
More negative than 72% of ticker scores this week
Strong Q2 results and medical countermeasure growth are offset by a lowered full-year guidance, a $191 million impairment charge, and pricing pressure for NARCAN.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+35.3%
Price is moving against the score
$6.55 vs $4.84 close before publication (Aug 7) · not market-adjusted
EBS chart →